Streiff Agathe, DiNardo James, Zaleski Katherine
From the Department of Anesthesiology, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, New York.
Department of Anesthesiology, Perioperative and Pain Medicine, Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts.
A A Pract. 2019 Jul 15;13(2):65-68. doi: 10.1213/XAA.0000000000000992.
Bivalirudin is a direct thrombin inhibitor that is used as a procedural anticoagulant during percutaneous coronary interventions and cardiac surgery for patients with heparin-resistant thrombosis or heparin-induced thrombocytopenia. There is a robust literature describing its safety and efficacy in adults; however, its use in the pediatric population is relatively rare, with dosing extrapolated from adult data. In this case report, we describe a 4-year-old with complex congenital heart disease and history of heparin-induced thrombocytopenia who required bivalirudin dose uptitration during cardiac catheterization.
比伐卢定是一种直接凝血酶抑制剂,在经皮冠状动脉介入治疗和心脏手术中,用于对肝素抵抗性血栓形成或肝素诱导的血小板减少症患者进行术中抗凝。有大量文献描述了其在成人中的安全性和有效性;然而,它在儿科人群中的使用相对较少,剂量是根据成人数据推断出来的。在本病例报告中,我们描述了一名患有复杂先天性心脏病且有肝素诱导的血小板减少症病史的4岁儿童,该儿童在心脏导管插入术期间需要增加比伐卢定的剂量。